ABSTRACT
Objective Globally, cardiovascular disease (CVD) has a significant role in morbidity and early death. This review’s objective is to provide a summary of the strengths and weaknesses in the variety of screening guidelines made by several international organizations for the early identification and prevention of CVD.
Methods As the reporting guideline for this review, we used Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR). We performed a scoping review using a few guideline-specific databases. We tabulated the main key differences between the included screening guidelines for CVD prevention and early detection from different perspectives.
Results We included a total of 20 unique guidelines that were developed by various organizations throughout the world and focused on screening for CVD prevention and early detection out of the 2,466 guidelines discovered by our search based on our eligibility criteria. We concluded that the target populations, CVD risk assessment techniques, outcomes, and categories of the chosen CVD prevention guidelines widely varied. Additionally, some guidelines adopted no grading scheme for their evidence, while others did not advocate the use of any imaging screening tools in their evaluation of the CVD risk.
Conclusions This scoping review highlights the areas of each guideline’s strengths and weaknesses and conducts a systematic comparison of a number of worldwide guidelines for CVD prevention and early diagnosis.
What is already known in this review?Based on the most recent evidence and consensus among experts, each nation creates its own set of guidelines for the early detection and prevention of CVD.
What this review adds This review conducted a systematic comparison and summarized the strengths and weaknesses of the various screening guidelines made by numerous international organizations for the early detection and prevention of CVD.
• How this review might affect research, practice or policy
This review provided opportunities to improve the future development of the clinical practice guidelines for CVD prevention and early detection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Universiti Brunei Darussalam, Brunei Darussalam.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
ABBREVIATIONS
- ABI
- Ankle-branchial Index
- ACCF/AHA
- The American College of Cardiology Foundation and the American Heart Association
- ADA
- American Diabetes Association
- AGREE II
- Appraisal of Guidelines for Research and Evaluation II
- AHA/ACC
- The American Heart Association and The American College of Cardiology
- ASSIGN
- ASsessing cardiovascular risk using SIGN guidelines to ASSIGN preventive treatment
- CAC
- Coronary Artery Calcium
- CAD
- coronary artery disease
- C-CHANGE
- Canadian Cardiovascular Harmonized National Guidelines Endeavour
- cIMT
- Carotid Intima-Media Thickness
- CPG
- Clinical practice guideline
- CT
- Computed Tomography
- CVD
- Cardiovascular disease
- CVDRA
- CVD risk assessment
- EAPC
- European Association of Preventive Cardiology
- ECG
- electrocardiogram
- ESC
- European Society of Cardiology
- GRADE
- The Grading of Recommendations Assessment, Development and Evaluation
- ISH
- International Society of Hypertension
- JBS
- Joint British Societies’ Guidelines
- MOH
- Ministry of Health
- MPI
- myocardial perfusion imaging
- NCDs
- Noncommunicable Diseases
- NCEP ATP
- National Cholesterol Education Program’s Adult Treatment Panel
- NHMRC
- National Health and Medical Research Council
- NHS
- National Health Services
- NICE
- National Institute for Health and Care Excellence
- NVDPA
- The National Vascular Disease Prevention Alliance
- PRISMA-ScR
- Systematic reviews and Meta-Analyses extension for Scoping Reviews
- PWV
- aortic pulse wave velocity
- SCORE
- Systematic Coronary Risk Estimation
- SCORE2-OP
- Updated SCORE for old people
- SHAPE
- Screening for Heart Attack Prevention and Education
- SIGN
- Scottish Intercollegiate Guidelines Network
- UK
- United Kingdom
- WHO
- World Health Organization
- WPR-A
- Western Pacific Region A
